Literature DB >> 23635517

Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients.

Ting Jia1, Abdul Rashid Qureshi, Vincent Brandenburg, Markus Ketteler, Peter Barany, Olof Heimburger, Fredrik Uhlin, Per Magnusson, Anders Fernström, Bengt Lindholm, Peter Stenvinkel, Tobias E Larsson.   

Abstract

BACKGROUND/AIMS: Treatment strategies for abnormal mineral metabolism in chronic kidney disease are largely based on achieving target ranges of biomarkers that vary considerably over time, yet determinants of their variability are poorly defined.
METHODS: Observational study including 162 patients of three dialysis cohorts (peritoneal dialysis, n = 78; hemodialysis, n = 49; hemodiafiltration, n = 35). Clinical and biochemical determinants of parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23) variability were analyzed in the peritoneal dialysis cohort. All cohorts were used for comparison of PTH and FGF23 intra-subject variability (intra-class correlation), and their intra-subject variability in different modes of dialysis was explored.
RESULTS: High PTH variability was independently associated with lower 25-hydroxyvitamin D concentration and factors of lipid and glucose metabolism, whereas high FGF23 variability was mainly associated with lower baseline serum phosphorous. These results were consistent in multivariate and sensitivity analyses. The intra-subject variability of FGF23 was lower than for PTH irrespective of dialysis mode.
CONCLUSIONS: Baseline vitamin D status and serum phosphorous are independent determinants of the longitudinal variation in PTH and FGF23, respectively. The clinical utility of FGF23 measurement remains unknown, yet it appears favorable based on its greater temporal stability than PTH in dialysis patients.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635517     DOI: 10.1159/000350537

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

1.  Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study.

Authors:  Valeria Cernaro; Silvia Lucisano; Valeria Canale; Annamaria Bruzzese; Daniela Caccamo; Giuseppe Costantino; Michele Buemi; Domenico Santoro
Journal:  J Nephrol       Date:  2017-04-11       Impact factor: 3.902

Review 2.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

3.  Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.

Authors:  Julia Wetzel; Stefan Pilz; Martin R Grübler; Astrid Fahrleitner-Pammer; Hans P Dimai; Dirk von Lewinski; Ewald Kolesnik; Sabine Perl; Christian Trummer; Verena Schwetz; Andreas Meinitzer; Evgeny Belyavskiy; Jakob Völkl; Cristiana Catena; Vincent Brandenburg; Winfried März; Burkert Pieske; Helmut Brussee; Andreas Tomaschitz; Nicolas D Verheyen
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-08-20       Impact factor: 3.738

Review 4.  FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.

Authors:  Anna Kurpas; Karolina Supeł; Karolina Idzikowska; Marzenna Zielińska
Journal:  Dis Markers       Date:  2021-05-17       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.